AVUGX
Price
$9.19
Change
+$0.14 (+1.55%)
Updated
Jul 2 closing price
Net Assets
1.93B
VIVIX
Price
$85.52
Change
+$0.75 (+0.88%)
Updated
Jul 2 closing price
Net Assets
245.01B
Interact to see
Advertisement

AVUGX vs VIVIX

AVUGX vs VIVIX Comparison Chart in %
View a ticker or compare two or three
VS
AVUGX vs. VIVIX commentary
Jul 04, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is AVUGX is a Buy and VIVIX is a Buy.

Interact to see
Advertisement
FUNDAMENTALS
Fundamentals
VIVIX has more cash in the bank: 245B vs. AVUGX (1.93B). VIVIX pays higher dividends than AVUGX: VIVIX (1.88) vs AVUGX (1.55). AVUGX was incepted earlier than VIVIX: AVUGX (9 years) vs VIVIX (28 years). AVUGX (0.78) is less costly to investors than VIVIX (0.03). AVUGX is a more actively managed with annual turnover of: 55.00 vs. VIVIX (8.00). AVUGX has a lower initial minimum investment than VIVIX: AVUGX (0) vs VIVIX (5000000). VIVIX annual gain was more profitable for investors over the last year : 22.78 vs. AVUGX (14.59). VIVIX return over 5 years is better than : 58.49 vs. AVUGX (4.49).
AVUGXVIVIXAVUGX / VIVIX
Total Expense Ratio0.750.032,500%
Annual Report Gross Expense Ratio0.780.032,600%
Fund Existence9 years28 years-
Gain YTD14.14014.77796%
Front LoadN/AN/A-
Min. Initial Investment05000000-
Min. Initial Investment IRAN/AN/A-
Net Assets1.93B245B1%
Annual Yield % from dividends1.551.8883%
Returns for 1 year14.5922.7864%
Returns for 3 years23.0054.0343%
Returns for 5 years4.4958.498%
Returns for 10 yearsN/A158.70-
View a ticker or compare two or three
Interact to see
Advertisement
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
FSCHX14.680.19
+1.31%
Fidelity Select Chemicals
MFWLX17.930.19
+1.07%
MFS Global Total Return R6
GIDWX19.930.02
+0.10%
Goldman Sachs US Eq Div and Premium R6
BSPIX869.440.03
N/A
iShares S&P 500 Index Institutional
TRCLX19.10-0.80
-4.02%
T. Rowe Price China Evolution Equity I